MaxCyte - Pole Position in Cell and Gene Therapy
MaxCyte Inc (LON:MXCT) is well-positioned to leverage its proprietary flow electroporation technology that is driving innovation, not only for its differentiated cell therapy platform CARMA but for a fast-growing list of leading industry partners. MXCT has more than 80 licensed programmes including more than 45 licensed for clinical use and has announced seven clinical/commercial partnership deals with front runners in the field of cell and gene therapy. The field is experiencing a huge step up in investment , rising by more than 77% year-on-year in 2018 because of increasing recognition of the potential to offer real hope to sufferers of often advanced and previously untreatable diseases by addressing the root causes, including targeting curative treatments.
Quick facts: MaxCyte Inc
Price: 132.8 GBX
Market Cap: £71.74 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE